CoChat

Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Although metastatic disease is responsible for the majority of cancer deaths, tests of novel immunotherapies in mouse tumour models often focus on primary tumours without determining whether these therapies also target metastatic disease. This study examined the impact of depleting Foxp3+regulatory T cells (Treg), on lung metastases, using a mouse model of breast cancer. After Treg-depletion, generation of an immune response to the primary tumour was a critical determinant for limiting development of metastasis. Indeed, resection of the primary tumour abrogated any effect of Treg-depletion on metastases. In addition, whilst the immune response, generated by the primary tumour, prevented metastases development, it had little impact on controlling established disease. Collectively, the data indicate that metastatic cells in the lung are not controlled by immune responses induced by the primary tumour. These findings indicate that targeting Tregs alone will not suffice for treating lung metastases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-020-02603-x

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Depletion of Tregs can control growth of primary 4T1 tumours and metastatic disease. a The effect of Treg-depletion on primary tumour growth was assessed as outlined. b The number of Tregs present within tumours or c tumour draining lymph nodes 7 days after administration of DTX (4 mice/group). An unpaired t test was performed to determine significance (P = 0.0268). d The average volumes of 4T1 tumours in Treg-depleted and Treg-replete mice are shown (6–7 mice/group). An unpaired two-tailed t test was performed at each time point, giving the following values: day 12 P = 0.0034, day 13 P = < 0.0001, day 16 p = < 0.0001 and day 21 p = 0.0002. e The impact of Treg-depletion on metastases following resection of primary tumours was assessed as outlined. f The number of metastatic colonies observed in the lungs of Treg-depleted and Treg-replete mice is shown (17–18 mice/group). A Mann–Whitney test was performed to determine whether there was a statistically significant difference between the groups (p = 0.0162)
Fig. 1 Depletion of Tregs can control growth of primary 4T1 tumours and metastatic disease. a The effect of Treg-depletion on primary tumour growth was assessed as outlined. b The number of Tregs present within tumours or c tumour draining lymph nodes 7 days after administration of DTX (4 mice/group). An unpaired t test was performed to determine significance (P = 0.0268). d The average volumes of 4T1 tumours in Treg-depleted and Treg-replete mice are shown (6–7 mice/group). An unpaired two-tailed t test was performed at each time point, giving the following values: day 12 P = 0.0034, day 13 P = < 0.0001, day 16 p = < 0.0001 and day 21 p = 0.0002. e The impact of Treg-depletion on metastases following resection of primary tumours was assessed as outlined. f The number of metastatic colonies observed in the lungs of Treg-depleted and Treg-replete mice is shown (17–18 mice/group). A Mann–Whitney test was performed to determine whether there was a statistically significant difference between the groups (p = 0.0162)CC BY · PubMed Central
Fig. 2 Control of metastatic disease after Treg-depletion is not linked to primary tumour size. The number of metastatic nodules was compared to the size of the primary tumour at the point of resection a or b the point at which DTx treatment was initiated (17–18 mice/group)
Fig. 2 Control of metastatic disease after Treg-depletion is not linked to primary tumour size. The number of metastatic nodules was compared to the size of the primary tumour at the point of resection a or b the point at which DTx treatment was initiated (17–18 mice/group)CC BY · PubMed Central
Fig. 3 Control of primary tumour growth predicts control of metastatic disease following Treg-depletion. Tumour growth rates were assessed in Treg-replete (a) and Treg-depleted (c) mice and compared prior to and after administration of DTx (b, d) (17–18 mice/group). Within the Treg-depleted group, mice were split into those with metastatic disease (e, f) and those without (g, h) (8–12 mice/group). A nonparametric one-tailed Wilcoxon signed-rank test was performed on the paired data sets shown in individual graphs
Fig. 3 Control of primary tumour growth predicts control of metastatic disease following Treg-depletion. Tumour growth rates were assessed in Treg-replete (a) and Treg-depleted (c) mice and compared prior to and after administration of DTx (b, d) (17–18 mice/group). Within the Treg-depleted group, mice were split into those with metastatic disease (e, f) and those without (g, h) (8–12 mice/group). A nonparametric one-tailed Wilcoxon signed-rank test was performed on the paired data sets shown in individual graphsCC BY · PubMed Central
Fig. 4 The presence of the primary tumour is essential for promoting control of metastatic disease after Treg-depletion. a DTx treatment was started after 4T1 tumours were resected. b Metastatic colonies in Treg-depleted and Treg-replete mice were compared, a Mann–Whitney test was used to determine no significant difference was observed between the number of metastatic colonies in Treg-replete versus Treg-depleted mice (15–18 mice/group). c Haematoxylin and eosin staining of paraffin-embedded sections from Treg-replete versus Treg-depleted metastatic lungs. d The number of CD3+ T cells (brown) per μm of metastatic nodules was calculated in the lungs of Treg-replete and Treg-depleted mice (9 metastatic nodules/group). e Representative staining of CD3+ T cells in metastatic lung nodules from Treg-replete and Treg-depleted mice
Fig. 4 The presence of the primary tumour is essential for promoting control of metastatic disease after Treg-depletion. a DTx treatment was started after 4T1 tumours were resected. b Metastatic colonies in Treg-depleted and Treg-replete mice were compared, a Mann–Whitney test was used to determine no significant difference was observed between the number of metastatic colonies in Treg-replete versus Treg-depleted mice (15–18 mice/group). c Haematoxylin and eosin staining of paraffin-embedded sections from Treg-replete versus Treg-depleted metastatic lungs. d The number of CD3+ T cells (brown) per μm of metastatic nodules was calculated in the lungs of Treg-replete and Treg-depleted mice (9 metastatic nodules/group). e Representative staining of CD3+ T cells in metastatic lung nodules from Treg-replete and Treg-depleted miceCC BY · PubMed Central
Fig. 5 Treg-depletion does not result in control of 4T1 tumour growth after intravenous injection. a Mice injected intravenously with 104 4T1 cells and seven days later administered DTx or PBS every other day (6 mice per group). b Metastatic colonies were enumerated 17 days later. c, d Lung T cells were was stained with AH1-dextramers (3–6 mice/group). Statistical significance was determined by unpaired two tailed T test, *p ≤ 0.05
Fig. 5 Treg-depletion does not result in control of 4T1 tumour growth after intravenous injection. a Mice injected intravenously with 104 4T1 cells and seven days later administered DTx or PBS every other day (6 mice per group). b Metastatic colonies were enumerated 17 days later. c, d Lung T cells were was stained with AH1-dextramers (3–6 mice/group). Statistical significance was determined by unpaired two tailed T test, *p ≤ 0.05CC BY · PubMed Central
Fig. 6 Immunisation following tumour resection, with recombinant vaccinia virus expressing the immunodominant peptide AH1, promotes tumour-specific T cells but does not control metastatic disease. a Mice were either treated with an irrelevant vaccine (Vac-NP) or a tumour antigen-specific vaccine (Vac-AH1) at day 1 post tumour resection and then either DTx or PBS treated from day 2 post tumour-resection,. At day 14 post tumour resection b the metastatic colonies in Treg-replete and Treg-depleted mice were compared (3—10 mice/group) and c splenocytes were stained with AH1-dextramer (3—10mice/group). d Representative CD8+ AH1-dextramer+ flow cytometry plots from mice (shown in c) vaccinated with either tumour-specific VAC-AH1, irrelevant VAC-NP or tumour-naïve mice
Fig. 6 Immunisation following tumour resection, with recombinant vaccinia virus expressing the immunodominant peptide AH1, promotes tumour-specific T cells but does not control metastatic disease. a Mice were either treated with an irrelevant vaccine (Vac-NP) or a tumour antigen-specific vaccine (Vac-AH1) at day 1 post tumour resection and then either DTx or PBS treated from day 2 post tumour-resection,. At day 14 post tumour resection b the metastatic colonies in Treg-replete and Treg-depleted mice were compared (3—10 mice/group) and c splenocytes were stained with AH1-dextramer (3—10mice/group). d Representative CD8+ AH1-dextramer+ flow cytometry plots from mice (shown in c) vaccinated with either tumour-specific VAC-AH1, irrelevant VAC-NP or tumour-naïve miceCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 16

Metadata

Authors
Hughes, E., Lauder, S. N., Smart, K., Bloom, A., Scott, J., Jones, E., Somerville, M., Browne, M., Blainey, A., Godkin, A., Ager, A., & Gallimore, A.
Affiliations
  • University of Manchester (GB)
  • Cardiff University (GB)
Corresponding author
Gallimore, Awen
Venue
Cancer Immunology, Immunotherapy
Published
2020-05-23
Volume
69
Issue
10
Pages
2063-2073
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W3026935474
Cited by
15
References
36
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 1
FWCI
0.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Immunology Immunotherapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
Funders
  • Tenovus (phd2013/L22)
  • Wales Cancer Research Centre
  • Cancer Research UK (C16731/A21200)
  • Breast Cancer Now (2019DecPR1377)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
regulatory T cells, Foxp3, Treg depletion, breast cancer, lung metastasis, antitumor immunity, primary tumor, tumor resection, metastasis suppression, cancer immunotherapy
MeSH terms
Animals, Female, Immunotherapy, Lung Neoplasms, Lymphocyte Depletion, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. https://app.cochat.ai/papers/10.1007/s00262-020-02603-x
The paper
Hughes, E., Lauder, S. N., Smart, K., Bloom, A., Scott, J., Jones, E., Somerville, M., Browne, M., Blainey, A., Godkin, A., Ager, A., & Gallimore, A. (2020). Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-020-02603-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.